1
Jason P Schrum, Noubar B Afeyan, Gregory J Sieczkiewicz, Stephane Bancel, Antonin de Fougerolles, Sayda M Elbashir: Engineered nucleic acids encoding a modified erythropoietin and their expression. Moderna Therapeutics, DT Ward P C, Donna T Ward, Jennifer F Bryan, April 29, 2014: US08710200 (40 worldwide citation)

Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.


2

3
Jason P Schrum, Stephane Bancel, Noubar B Afeyan: Engineered nucleic acids and methods of use thereof. Moderna Therapeutics, DT Ward PC, Donna T Ward, Jennifer F Bryan, November 10, 2015: US09181319 (8 worldwide citation)

Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to imp ...


4
Stephane Bancel, Jason P Schrum, Alexander Aristarkhov: Engineered nucleic acids and methods of use thereof. Moderna Therapeutics, Wolf Greenfield & Sacks P C, October 11, 2016: US09464124 (4 worldwide citation)

Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent microbial infection, or to i ...


5

6
Antonin de Fougerolles, Atanu Roy, Jason P Schrum, Suhaib Siddiqi, Paul Hatala, Stephane Bancel: Modified nucleosides, nucleotides, and nucleic acids, and uses thereof. Moderna Therapeutics, Clark & Elbing, August 30, 2016: US09428535 (1 worldwide citation)

The present disclosure provides methods of increasing the level of a polypeptide of interest in a mammalian subject by administering a polynucleotide having one or more chemical modifications and a Protein:Cytokine ratio of greater than 100.


7

8

9
Tirtha Chakraborty, Stephane Bancel, Stephen G Hoge, Atanu Roy, Antonin de Fougerolles, Noubar B Afeyan: Terminally modified RNA. ModernaTx, Nelson Mullins Riley & Scarborough, Amy E Mandragouras Esq, March 21, 2017: US09597380

The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.


10
Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M Wood, Paul Hatala, Jason P Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild: Modified polynucleotides for the production of oncology-related proteins and peptides. ModernaTX, Clark & Elbing, March 7, 2017: US09587003

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.